Copyright ©2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved

Non-Steroidal Anti-Inflammatory Drugs Market - Global Market Share, Trends, Analysis and Forecast 2023 – 2032


Report code : IS768, Status : Published, Published on: Aug, 2021, Pages : 156 Pages, Format : PDF/PPT/Excel

Buying Options


The global non-steroidal anti-inflammatory drugs market size was estimated to be US$ 16.1 billion in 2020 and is expected to reach US$ 31 billion by 2031 at a CAGR of 6.1%.

Anti-inflammatory drugs are the drugs that are utilized to deal with conditions like Asthma, joint pain, Chronic obstructive pulmonary disease (COPD) and different illnesses. These drugs are much of the time recommended, lessening torment caused because of irritation. The most normally endorsed torment alleviating drugs are diclofenac and ibuprofen. These are viewed as the principal line of treatment in pain mitigation system because of three essential properties, namely, pain relieving, antipyretic, and anti-inflammatory.

NSAID gels have likewise been demonstrated to ease the aggravation and have lesser incidental effects. Specialists have been turning towards recommending the most current type of Anti-Irritation drugs, called Biologics. The occurrence of aggravation and agony causing illnesses is upsurging step by step around the world. It is further expanding the take-up of Non-Steroidal Anti-Inflammatory Drugs to fix and treat ongoing and intense torment. Subsequently, there has been an increment in the Anti-inflammatory drugs market in the previous decade, and the pattern appears to just increment with a lot better rate.

Be that as it may, rigid FDA guidelines for the medication endorsement of new medication might hamper the worldwide skin non-steroidal anti-inflammatory drugs market during 2022-2032. Also, notwithstanding, section of new imaginative restorative analgesics, severe unofficial laws, and incidental effect related with non-steroidal anti-inflammatory drugs limit the non-steroidal anti-inflammatory drugs market.

North America rules the non-steroidal anti-inflammatory drugs market, trailed by Europe, because of expansion in geriatric populace experiencing bone and joint issues. Asia Pacific is a developing business sector for non-steroidal anti-inflammatory drugs attributable to rising medical services framework.

Expansion in bone and joint agony illnesses like osteoarthritis, and rheumatoid joint pain among people is the key driving component which is postulated to support the worldwide Non-Steroidal Anti-Inflammatory Drugs market development during 2022-2032.

Global Non-steroidal anti-inflammatory drugs Market Value Share Analysis, by Geography (2022)

The report titled “Global Non-steroidal anti-inflammatory drugs Market - Global Market Share, Trends, Analysis and Forecasts, 2023-2032”, wherein 2021 is historic period, 2022 is the base year, and 2023 to 2032 is forecast period. Additionally, the study takes into consideration the competitive landscape, wherein the report would provide company overview and market outlook for leading players in the Global Non-steroidal anti-inflammatory drugs Market. Furthermore, the report would reflect the key developments, global & regional sales network, business strategies, research & development activities, employee strength, and key executive, for all the major players operating in the market.

The global non-steroidal anti-inflammatory drugs market is segmented on the product type, indication, end-users, and region. Based on product type, the non-steroidal anti-inflammatory drugs market is segmented into creams, gel, ointment, spray, rubs, solution, and others. Based on indication, the non-steroidal anti-inflammatory drugs market is segmented into anti-inflammatory, analgesic, swelling, stiffness, skin infections and others. Based on end user, the non-steroidal anti-inflammatory drugs market is segmented into hospitals, specialty clinics and others. Based on distribution channel, the non-steroidal anti-inflammatory drugs market is segmented into hospital pharmacy, retail pharmacy others.

Based on geography, the Global Non-steroidal anti-inflammatory drugs Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South America. North America is sub-segmented into the United States, Canada, and Rest of North America. Europe is sub-segmented into Germany, United Kingdom, Italy, France, Spain, and Rest of Europe. Asia Pacific is sub-segmented into China, Japan, India, Australia, and Rest of Asia Pacific. Middle East & Africa is sub-segmented into Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa. South America is sub-segmented into Brazil and Rest of South America.

The research provides in-depth analysis of prominent players holding majority share of the global market with a focus on all operating business segment and would identify the segment of the company focusing on Global Non-steroidal anti-inflammatory drugs Market. Further, market share of prominent companies in the Global Non-steroidal anti-inflammatory drugs Market would also be estimated. 

The study takes into consideration the key competitive information such as business strategy, product portfolio, key development, swot analysis, and research and development focus of all the non-steroidal anti-inflammatory drugs companies. The Global Non-steroidal anti-inflammatory drugs Market study would take into consideration the participants engaged throughout the supply chain and value chain of the market, along with their contribution. Product portfolio would focus on all the products under the non-steroidal anti-inflammatory drugs business segment of the company. Similarly, the recent development section would focus on the latest developments of company such as strategic alliances and partnerships, merger and acquisition, new product launched and geographic expansion in the Global Non-steroidal anti-inflammatory drugs Market.

The key players of the Global Non-steroidal anti-inflammatory drugs Market are Novartis AG, GlaxoSmithKline plc., Horizon Therapeutics plc., Tolmar Pharmaceuticals, Inc., Apotex Inc., Perrigo Company plc, and others.

Global Non-steroidal anti-inflammatory drugs Market Key Segments:

Based on product type  

  • Creams
  • Gel
  • Ointment
  • Spray
  • Rubs
  • Solution
  • Others

Based on indication

  • Anti-inflammatory
  • Analgesic
  • Swelling
  • Stiffness
  • Skin infections
  • Others

Based on end user 

  • Hospitals
  • Specialty clinics
  • Others

Based on distribution channel

  • Hospital pharmacy
  • Retail pharmacy
  • Others

By Region

  • North America
    • United States
    • Canada
    • Rest of North America
  • Europe
    • Germany
    • United Kingdom
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East & Africa
    •  UAE
    • Saudi Arabia
    • South Africa
    • Rest of the Middle East & Africa
  • South America
    • Brazil
    • Rest of South America

Frequently asked questions about this report

How big is the Non-steroidal anti-inflammatory drugs Market?

The global Non-steroidal anti-inflammatory drugs market was worth US$ 16.1 billion in 2020.

What is the estimated growth rate of Non-steroidal anti-inflammatory drugs Market?

The global Non-steroidal anti-inflammatory drugs market is expected to register a CAGR of 6.1% between 2022 and 2032.

Which are the prominent players active in the Non-steroidal anti-inflammatory drugs Market?

Novartis AG, GlaxoSmithKline plc., Horizon Therapeutics plc., Tolmar Pharmaceuticals, Inc., Apotex Inc., Perrigo Company plc are few prominent players active in the market.

Which region is contributing significantly to the global Non-steroidal anti-inflammatory drugs Market?

North America is the principal contributor to the global Non-steroidal anti-inflammatory drugs market.

What are the end-use segments in the Non-steroidal anti-inflammatory drugs market?

The end-use segments in Non-steroidal anti-inflammatory drugs market are Hospital pharmacy and Retail pharmacy.